PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery

Stimulators and activators of soluble guanylate cyclase for urogenital disorders

(2017) Fabiola Z. Mónica et al.   Nature Reviews Urology

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

(2017) Simon D Harding et al.   NUCLEIC ACIDS RESEARCH

Pulmonary Hypertension Therapy and a Systematic Review of Efficacy and Safety of PDE-5 Inhibitors

(2017) Chinwe Unegbu et al.   PEDIATRICS

New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)

(2016) Giovanni Ribaudo et al.   CURRENT MEDICINAL CHEMISTRY

Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

(2016) Mauro Gacci et al.   EUROPEAN UROLOGY

Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015)

(2016) Konstantinos Hatzimouratidis et al.   Journal of Sexual Medicine

Pediatric Cardiac Intensive Care Society 2014 Consensus Statement

(2016) John S. Kim et al.   Pediatric Critical Care Medicine

Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study

(2014) Matthias Oelke et al.   BJU INTERNATIONAL

Nitric oxide synthase regulation of cardiac excitation–contraction coupling in health and disease

(2014) Jillian N. Simon et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH–LUTS

(2014) Selim Cellek et al.   Nature Reviews Urology

Comparative Effectiveness of Oral Drug Therapies for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia: A Systematic Review and Network Meta-Analysis

(2014) Xinghuan Wang et al.   PLoS One

Tadalafil Once Daily Improves Ejaculatory Function, Erectile Function, and Sexual Satisfaction in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Erectile Dysfunction: Results from a Randomized, Placebo‐ and Tamsulosin-Controlled, 12-Week Double-Blind Study

(2013) François Giuliano et al.   Journal of Sexual Medicine

Nitric Oxide Synthases in Heart Failure

(2012) Ricardo Carnicer et al.   ANTIOXIDANTS & REDOX SIGNALING

PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update

(2012) Serap Gur et al.   CURRENT PHARMACEUTICAL DESIGN

A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with α-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

(2012) Mauro Gacci et al.   EUROPEAN UROLOGY

Sildenafil Effect on the Human Bladder Involves the L-cysteine/Hydrogen Sulfide Pathway: A Novel Mechanism of Action of Phosphodiesterase Type 5 Inhibitors

(2012) Ferdinando Fusco et al.   EUROPEAN UROLOGY

Avanafil, a Potent and Highly Selective Phosphodiesterase-5 Inhibitor for Erectile Dysfunction

(2012) Jun Kotera et al.   JOURNAL OF UROLOGY

Prophylactic Effect of Tadalafil on Bladder Function in a Rat Model of Chronic Bladder Ischemia

(2012) Masanori Nomiya et al.   JOURNAL OF UROLOGY

Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

(2011) Thérèse Keravis et al.   BRITISH JOURNAL OF PHARMACOLOGY

Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary Disease

(2011) Johannes-Peter Stasch et al.   CIRCULATION

Phosphodiesterase Type 5 Inhibitors in the Management of Non-neurogenic Male Lower Urinary Tract Symptoms: Critical Analysis of Current Evidence

(2011) Juan I. Martínez-Salamanca et al.   EUROPEAN UROLOGY

Novel roles of cAMP/cGMP-dependent signaling in platelets

(2011) A. SMOLENSKI   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Mechanisms of Penile Erection and Basis for Pharmacological Treatment of Erectile Dysfunction

(2011) K.- E. Andersson   PHARMACOLOGICAL REVIEWS

Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions

(2011) Sharron H. Francis et al.   PHYSIOLOGICAL REVIEWS

Phosphodiesterase-5 Inhibitors for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis

(2011) Liangren Liu et al.   UROLOGY

Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle

(2010) S Oger et al.   BRITISH JOURNAL OF PHARMACOLOGY

The future is today: emerging drugs for the treatment of erectile dysfunction

(2010) Maarten Albersen et al.   EXPERT OPINION ON EMERGING DRUGS

Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment

(2009) Claus G. Roehrborn et al.   BJU INTERNATIONAL

Characterization of Phosphodiesterase Type 5 Expression and Functional Activity in the Human Male Lower Urinary Tract

(2009) Benedetta Fibbi et al.   Journal of Sexual Medicine

Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum

(2008) Haroldo A. Toque et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

A Randomised, Placebo-Controlled Study to Assess the Efficacy of Twice-Daily Vardenafil in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

(2008) Christian G. Stief et al.   EUROPEAN UROLOGY